Development of
Animals
Antigens, Surface
/ immunology
Antineoplastic Agents, Immunological
/ chemistry
Cell Line, Tumor
Glutamate Carboxypeptidase II
/ immunology
Heterocyclic Compounds, 1-Ring
/ chemistry
Humans
Immunoconjugates
/ chemistry
Immunoglobulin Variable Region
/ chemistry
Lutetium
/ pharmacokinetics
Male
Mice, Nude
PC-3 Cells
Precision Medicine
/ methods
Prostatic Neoplasms
/ drug therapy
Radioisotopes
/ pharmacokinetics
Radiopharmaceuticals
/ chemistry
Single Photon Emission Computed Tomography Computed Tomography
Single-Chain Antibodies
/ chemistry
Tissue Distribution
Xenograft Model Antitumor Assays
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 06 2020
09 06 2020
Historique:
received:
11
12
2019
accepted:
18
05
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
17
12
2020
Statut:
epublish
Résumé
The clinical translation of theranostic
Identifiants
pubmed: 32518372
doi: 10.1038/s41598-020-66285-2
pii: 10.1038/s41598-020-66285-2
pmc: PMC7283306
doi:
Substances chimiques
Antigens, Surface
0
Antineoplastic Agents, Immunological
0
Heterocyclic Compounds, 1-Ring
0
Immunoconjugates
0
Immunoglobulin Variable Region
0
Radioisotopes
0
Radiopharmaceuticals
0
Single-Chain Antibodies
0
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9313Références
Litwin, M. S. & Tan, H. J. The diagnosis and treatment of prostate cancer a review. Jama-Journal of the American Medical Association 317, 2532–2542 (2017).
doi: 10.1001/jama.2017.7248
Evans, J. D. et al. Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract. Radiat. Oncol. 8, 28–39 (2018).
doi: 10.1016/j.prro.2017.07.011
Bouchelouche, K., Turkbey, B. & Choyke, P. L. PSMA PET and radionuclide therapy in prostate cancer. Semin. Nucl. Med. 46, 522–535 (2016).
doi: 10.1053/j.semnuclmed.2016.07.006
Garcia-Perez, F. O. et al. Head to head comparison performance of Tc-99m-EDDA/HYNIC-iPSMA SPECT/CT and Ga-68-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients. Am. J. Nucl. Med. Molec. Imaging 8, 332–340 (2018).
Rahbar, K., Afshar-Oromieh, A., Jadvar, H. & Ahmadzadehfar, H. PSMA theranostics: current status and future directions. Mol. Imaging 17 (2018).
Santos-Cuevas, C. et al. Lu-177-DOTA-HYNIC-Lys(Nal)-Urea-Glu: biokinetics, dosimetry, and evaluation in patients with advanced prostate cancer. Contrast Media Mol. Imaging, 5247153 (2018).
Fendler, W. P. et al. Preliminary experience with dosimetry, response and patient reported outcome after Lu-177-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 8, 3581–3590 (2017).
doi: 10.18632/oncotarget.12240
Virgolini, I., Decristoforo, C., Haug, A., Fanti, S. & Uprimny, C. Current status of theranostics in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 45, 471–495 (2018).
doi: 10.1007/s00259-017-3882-2
Smith-Jones, P. M. et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44, 610–617 (2003).
pubmed: 12679407
Kratochwil, C., Afshar-Oromieh, A., Kopka, K., Haberkorn, U. & Giesel, F. L. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin. Nucl. Med. 46, 405–418 (2016).
doi: 10.1053/j.semnuclmed.2016.04.004
Colombatti, M. et al. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One 4 (2009).
Lutje, S. et al. Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody. J. Nucl. Med. 55, 995–1001 (2014).
doi: 10.2967/jnumed.114.138180
Frigerio, B. et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. EUR J CANCER 49, 2223–2232 (2013).
doi: 10.1016/j.ejca.2013.01.024
Frigerio, B. et al. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunol. Lett. 168, 105–110 (2015).
doi: 10.1016/j.imlet.2015.09.012
Frigerio, B. et al. Full preclinical validation of the I-123-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Oncotarget 8, 10919–10930 (2017).
doi: 10.18632/oncotarget.14229
Kobayashi, H. et al. Pharmacokinetics of In-111- and I-125-labeled antiTac single-chain Fv recombinant immunotoxin. J. Nucl. Med. 41, 755–762 (2000).
pubmed: 10768579
Boros, E. & Holland, J. P. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers. J. Label. Compd. Radiopharm. 61, 652–671 (2018).
doi: 10.1002/jlcr.3590
Forrer, F. et al. In vitro characterization of Lu-177-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur. J. Nucl. Med. Mol. Imaging 36, 1443–1452 (2009).
doi: 10.1007/s00259-009-1120-2
Parker, S. A., Diaz, I. L. C., Anderson, K. A. & Batt, C. A. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591. Protein Expr. Purif. 89, 136–145 (2013).
doi: 10.1016/j.pep.2013.02.016
Luna-Gutierrez, M., Hernandez-Jimenez, T., Serrano-Espinoza, L., Pena-Flores, A. & Soto-Abundiz, A. Freeze-dried multi-dose kits for the fast preparation of Lu-177-Tyr(3)-octreotide and Lu-177-PSMA(inhibitor) under GMP conditions. J. Radioanal. Nucl. Chem. 314, 2181–2188 (2017).
doi: 10.1007/s10967-017-5595-1
Hernandez-Jimenez, T. et al. Lu-177-DOTA-HYNIC-Lys(Nal)-Urea-Glu: synthesis and assessment of the ability to target the prostate specific membrane antigen. J. Radioanal. Nucl. Chem. 318, 2059–2066 (2018).
doi: 10.1007/s10967-018-6239-9
Melendez-Alafort, L., Rosato, A., Ferro-Flores, G., Penev, I. & Uzunov, N. Development of a five-compartimental model and software for pharmacokinetic studies. C. R. Acad. Bulg. Sci. 70, 1649–1654 (2017).
Kuo, H. T. et al. Enhancing treatment efficacy of Lu-177-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol. Pharm. 15, 5183–5191 (2018).
doi: 10.1021/acs.molpharmaceut.8b00720
Akizawa, H., Uehara, T. & Arano, Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv. Drug Deliv. Rev. 60, 1319–1328 (2008).
doi: 10.1016/j.addr.2008.04.005
Umbricht, C. A., Benesova, M., Schibli, R. & Muller, C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol. Pharm. 15, 2297–2306 (2018).
doi: 10.1021/acs.molpharmaceut.8b00152
Benesova, M., Umbricht, C. A., Schibli, R. & Muller, C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol. Pharm. 15, 934–946 (2018).
doi: 10.1021/acs.molpharmaceut.7b00877
Banerjee, S. R. et al. Evaluation of In-111-DOTA-5D3, a surrogate SPECT imaging agent for radioimmunotherapy of prostate-specific membrane antigen. J. Nucl. Med. 60, 400–406 (2019).
doi: 10.2967/jnumed.118.214403
Lutje, S. et al. Targeting human prostate cancer with In-111-labeled D2B IgG, F(ab ‘)(2) and Fab fragments in nude mice with PSMA-expressing xenografts. Contrast Media Mol. Imaging 10, 28–36 (2015).
doi: 10.1002/cmmi.1596
Price, E. W. & Orvig, C. Matching chelators to radiometals for radiopharmaceuticals. Chemical Society Reviews 43, 260–290 (2014).
doi: 10.1039/C3CS60304K
Khawar, A. et al. Prediction of normal organ absorbed doses for 177Lu Lu-PSMA-617 using 44Sc Sc-PSMA-617 pharmacokinetics in patients with metastatic castration resistant prostate carcinoma. Clin. Nucl. Med. 43, 486–491 (2018).
doi: 10.1097/RLU.0000000000002102
Bacich, D. J., Pinto, J. T., Tong, W. P. & Heston, W. D. W. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm. Genome 12, 117–123 (2001).
doi: 10.1007/s003350010240
Wirtz, M. et al. Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. EJNMMI Res. 8 (2018).
Behr, T. M. et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J. Nucl. Med. 37, 829–833 (1996).
pubmed: 8965154
Wu, A. M. & Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology 23, 1137–1146 (2005).
doi: 10.1038/nbt1141